Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aptorum Group Limited - Class A Ordinary Shares (NQ:APM)

0.8075 +0.0671 (+9.06%)
Streaming Delayed Price Updated: 3:28 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aptorum Group Limited - Class A Ordinary Shares

< Previous 1 2 3 Next >
News headline image
Aptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares Deficiency
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Announces 1-for-10 Reverse Stock Split
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Announces Completion of $3 Million Convertible Note due 2023
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Announces Offering of $3 Million Convertible Note due 2023
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
Via ACCESSWIRE
News headline image
Aptorum Announces Publication of a Co-authored Paper on Development and Validation of a Sensitive Liquid Chromatography with Time-Of-Flight Mass Spectrometry Assay for In Vivo Pharmacokinetic Study of Epigallocatechin-gallate octaacetate (Pro-EGCG)
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
Via ACCESSWIRE
News headline image
Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Limited to Present at the H.C. Wainwright Annual Global Investment Conference, September 13-16, 2022
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
Via ACCESSWIRE
The Global Pharmaceutical Industry is Accelerating; Aptorum Group Has Received Orphan Drug Designation from US FDA for Its SACT-1
Via ACN Newswire
Topics Intellectual Property
News headline image
Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business Update
From Aptorum Group Limited
Via Business Wire
News headline image
First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods Granted
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Announces Updates on the Clinical Validation of its RPIDD Infectious Disease Liquid Biopsy Technology
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel Biomarkers
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Limited Announces Results of 2021 Annual General Meeting of Shareholders
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 2, 2021
From Aptorum Group Limited
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.